Top Markets
Coin of the day
Carmell Therapeutics Corporation Carmell Therapeutics Corporation

Carmell Therapeutics Corporation

CTCX
Kedudukan dalam Saham #36666
Carmell Therapeutics Corporation (CTCX) specializes in the creation of... Carmell Therapeutics Corporation (CTCX) specializes in the creation of plasma-based bioactive materials (PBMs) aimed at catalyzing tissue regeneration and repair following injury, illness, or the effects of aging. Their flagship product, CT-101, is a versatile accelerant with a dual focus. For orthopedic and dental applications, it's designed to enhance bone healing in cases such as tibia fractures, foot and ankle fusions, spinal fusions, and also serves as a dental bone graft substitute and bone void filler. Furthermore, CT-101 acts as a tissue healing accelerant, addressing conditions like androgenetic alopecia (pattern baldness) and persistent chronic wounds. Established in 2008, the company operates from its headquarters in Pittsburgh, Pennsylvania.
Harga Saham
$0.117
Disegerakkan terakhir: 2025-04-04
Modal Pasaran
$2.45M
Perubahan (1 hari)
-13.59%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Carmell Therapeutics Corporation (CTCX)

Kategori

Pendapatan untuk Carmell Therapeutics Corporation (CTCX)
Pendapatan pada Jun 2026 TTM: $-6.79M
Menurut laporan kewangan terkini Carmell Therapeutics Corporation, pendapatan semasa syarikat ialah $-6.79M. Pada tahun 2023, syarikat memperoleh pendapatan sebanyak $-16.21M, penurunan berbanding pendapatan pada tahun 2022 yang berjumlah $-9.05M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Carmell Therapeutics Corporation dari 2021 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
2026 (TTM) $-6.79M -36.81%
2024 $-10.75M -33.68%
2023 $-16.21M 79.04%
2022 $-9.05M 2,647.97%
2021 $-329.38K 0.00%
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
$5.27B -77,766.65%
US
$1.95B -28,821.01%
NL
- -
CH
- -
KR
$3.01B -44,355.62%
BE